Panigaj M, Basu Roy T, Skelly E, Chandler M, Wang J, Ekambaram S
ACS Nano. 2025; 19(2):1865-1883.
PMID: 39760461
PMC: 11757000.
DOI: 10.1021/acsnano.4c13663.
Jia X, Yuan B, Wang W, Wang K, Ling D, Wei M
J Nanobiotechnology. 2024; 22(1):787.
PMID: 39710679
PMC: 11663325.
DOI: 10.1186/s12951-024-03065-4.
Kaplan J, Ye W, Kileen H, Liang Z, Tran A, Chi J
J Neurosci. 2024; 45(6).
PMID: 39592233
PMC: 11800744.
DOI: 10.1523/JNEUROSCI.1560-24.2024.
Amiri M, Moaveni A, Zolbin M, Shademan B, Nourazarian A
Front Immunol. 2024; 15:1462697.
PMID: 39582866
PMC: 11581867.
DOI: 10.3389/fimmu.2024.1462697.
Haug M, Haddad-Velioglu S, Berger M, Enz A, Zang J, Neuhauss S
Invest Ophthalmol Vis Sci. 2024; 65(12):44.
PMID: 39475940
PMC: 11536201.
DOI: 10.1167/iovs.65.12.44.
Targeting mRNA-coding genes in prostate cancer using CRISPR/Cas9 technology with a special focus on androgen receptor signaling.
Tabibian M, Moghaddam F, Motevaseli E, Ghafouri-Fard S
Cell Commun Signal. 2024; 22(1):504.
PMID: 39420406
PMC: 11484332.
DOI: 10.1186/s12964-024-01833-1.
Focusing on CD8 T-cell phenotypes: improving solid tumor therapy.
Yao Z, Zeng Y, Liu C, Jin H, Wang H, Zhang Y
J Exp Clin Cancer Res. 2024; 43(1):266.
PMID: 39342365
PMC: 11437975.
DOI: 10.1186/s13046-024-03195-5.
Cell-targeted gene modification by delivery of CRISPR-Cas9 ribonucleoprotein complexes in pseudotyped lentivirus-derived nanoparticles.
Nielsen I, Rovsing A, Janns J, Thomsen E, Ruzo A, Boggild A
Mol Ther Nucleic Acids. 2024; 35(4):102318.
PMID: 39329149
PMC: 11426049.
DOI: 10.1016/j.omtn.2024.102318.
Therapeutic CRISPR epigenome editing of inflammatory receptors in the intervertebral disc.
Stover J, Trone M, Weston J, Lewis C, Levis H, Farhang N
Mol Ther. 2024; 32(11):3955-3973.
PMID: 39295148
PMC: 11573609.
DOI: 10.1016/j.ymthe.2024.09.022.
Engineered IRES-mediated promoter-free insulin-producing cells reverse hyperglycemia.
Li Y, Younis D, He C, Ni C, Liu R, Zhou Y
Front Endocrinol (Lausanne). 2024; 15:1439351.
PMID: 39279997
PMC: 11392723.
DOI: 10.3389/fendo.2024.1439351.
Compared to other NHEJ factors, DNA-PK protein and RNA levels are markedly increased in all higher primates, but not in prosimians or other mammals.
Pascarella G, Conner K, Goff N, Carninci P, Olive A, Meek K
DNA Repair (Amst). 2024; 142:103737.
PMID: 39128395
PMC: 11515020.
DOI: 10.1016/j.dnarep.2024.103737.
CRISPR-based genetic screens advance cancer immunology.
Cao Y, Li X, Pan Y, Wang H, Yang S, Hong L
Sci China Life Sci. 2024; 67(12):2554-2562.
PMID: 39048715
DOI: 10.1007/s11427-023-2571-0.
Neuroepigenetic Editing.
Hamilton P, Lim C, Nestler E, Heller E
Methods Mol Biol. 2024; 2842:129-152.
PMID: 39012593
PMC: 11520296.
DOI: 10.1007/978-1-0716-4051-7_6.
Advances in and Perspectives on Transgenic Technology and CRISPR-Cas9 Gene Editing in Broccoli.
Zhang L, Meng S, Liu Y, Han F, Xu T, Zhao Z
Genes (Basel). 2024; 15(6).
PMID: 38927604
PMC: 11203320.
DOI: 10.3390/genes15060668.
Characterization of HIF-1α Knockout Primary Human Natural Killer Cells Including Populations in Allogeneic Glioblastoma.
Nakazawa T, Morimoto T, Maeoka R, Yamada K, Matsuda R, Nakamura M
Int J Mol Sci. 2024; 25(11).
PMID: 38892084
PMC: 11173110.
DOI: 10.3390/ijms25115896.
Role of Medaka () in Resistance to Nervous Necrosis Virus Infection.
Li W, Wang Z, Liang J, Xia B, Chen R, Chen T
Animals (Basel). 2024; 14(11).
PMID: 38891634
PMC: 11171044.
DOI: 10.3390/ani14111587.
Revolutionizing Lung Cancer Treatment: Innovative CRISPR-Cas9 Delivery Strategies.
Singh D
AAPS PharmSciTech. 2024; 25(5):129.
PMID: 38844700
DOI: 10.1208/s12249-024-02834-6.
Neocarzilin Inhibits Cancer Cell Proliferation via BST-2 Degradation, Resulting in Lipid Raft-Trapped EGFR.
Braun J, Hu Y, Jauch A, Gronauer T, Mergner J, Bach N
JACS Au. 2024; 4(5):1833-1840.
PMID: 38818080
PMC: 11134574.
DOI: 10.1021/jacsau.4c00039.
High-Throughput Screening of PAM-Flexible Cas9 Variants for Expanded Genome Editing in the Silkworm ().
Sun L, Zhang T, Lan X, Zhang N, Wang R, Ma S
Insects. 2024; 15(4).
PMID: 38667371
PMC: 11050708.
DOI: 10.3390/insects15040241.
Genome Editing in Brassica juncea Using CRISPR/Cas9 Technology.
Ahmad N, Fatima S, Hundleby P, Mehboob-Ur-Rahman
Methods Mol Biol. 2024; 2788:337-354.
PMID: 38656524
DOI: 10.1007/978-1-0716-3782-1_20.